Atezolizumab plus WT1 vaccine with chemo for pleural mesothelioma
Treatments studied
Part of Cancer, Genetic & congenital, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial studies a treatment plan that combines an immune drug (atezolizumab) and a personalized cancer vaccine (WT1/DC) with standard first-line chemotherapy for epithelioid malignant pleural mesothelioma that cannot be removed with surgery. It aims to improve control of the cancer by helping the immune system work alongside chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed epithelioid malignant pleural mesothelioma that cannot be fully removed by surgery
- You are at least 18 years old and can sign informed consent
- You are generally well (performance status 0–1) and can follow study visits and procedures
- Blood tests and organ function are within allowed limits (or in specific cases, allowed with metastases and transfusion rules)
- Your cancer has not been treated with prior treatment specifically for this mesothelioma
- You do not have certain immune-related illnesses, uncontrolled infections, or lung inflammation history that could make immunotherapy unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding nivolumab (an immunotherapy) to a one-time “light-based” treatment during a lung procedure can control malignant pleural mesothelioma that can’t be surgically removed. You may be eligible if your cancer has come back or progressed after prior platinum chemotherapy, and if your tumor is reachable for the light treatment during thoracoscopy.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This trial tests whether giving chemotherapy and immunotherapy before planned surgery can make inoperable pleural mesothelioma operable. It is for people with a specific type of mesothelioma (epithelioid) that cannot be removed right away, to see if the treatment shrinks the tumor enough for surgery later.
This study tests whether atezolizumab given after surgery and chemotherapy can lower the risk of mesothelioma coming back compared with a placebo. It may help by boosting the immune system to control remaining microscopic cancer cells.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests adding a drug called fianlimab to another drug (cemiplimab) plus chemotherapy for people with a type of lung cancer called pleural mesothelioma. It aims to see if the combination is more effective than cemiplimab plus chemo alone.
Hear when a new Malignant Pleural Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.